Who Paid My Doc
Robert Carter Jones
Anesthesiology Greenwood Village, CO Medical Doctor
NPI 1063568731 CMS profile 1048498
8000 E Maplewood Ave Ste 200, Greenwood Village, CO 80111
General payments
$37,056
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$11,427
Through program year 2020, Robert Carter Jones of Greenwood Village, CO is reported in the CMS Open Payments database as having received $37,056 across 55 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $11,427 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 99th percentile of Anesthesiology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
2 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2020 | General | $5,070 | 4 | |
| 2019 | General | $31,987 | 51 |
Beside peers
- Robert Carter Jones
- Anesthesiology median
- Middle half of Anesthesiology
- National median
In program year 2025, general payments to Robert Carter Jones were reported at $0. Among 18,548 Anesthesiology profiles paid that year, the median was $58 and the middle half received between $26 and $153.
Show as a table
| Year | Robert Carter Jones | Anesthesiology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $31,987 | $72 | $23–$151 | $163 |
| 2020 | $5,070 | $36 | $17–$120 | $114 |
| 2021 | $0 | $49 | $21–$135 | $132 |
| 2022 | $0 | $52 | $22–$144 | $149 |
| 2023 | $0 | $53 | $23–$143 | $160 |
| 2024 | $0 | $55 | $25–$150 | $164 |
| 2025 | $0 | $58 | $26–$153 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Billing to Medicare
Part B · data year 2024 · 65 billing codesPaid by Medicare
$40,912
Medicare patients
266
Services billed
320
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 65% | |
| Depression | 33% | |
| Ischemic heart disease | 32% | |
| Chronic kidney disease | 30% | |
| Atrial fibrillation | 26% | |
| Diabetes | 25% | |
| Heart failure | 21% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
55 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
Anesthesiology in Colorado
Practitioners in the same specialty and state, ranked by reported value.
All Anesthesiology
Everyone recorded under this specialty, nationwide.
Doctors in Colorado
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.